AER-271

AER-271

A655960-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

AER-271 是一种 AER-270 的膦酸酯前药，是aquaporin-4抑制剂，有用于急性缺血性中风的研究潜力。 AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic stroke In Vivo AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest . AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mice (C57BL/6J, 8-12 week-old, 25-30 g)Dosage: 5 mg/kg Administration: Treated by i.p. injection Result: Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62. IC50& Target:Aquaporin-4 (AQP4)

AER-271是AER-270的一种膦酸盐原药衍生物，是一种用于研究急性缺血性中风的水通道蛋白-4（AQP4）抑制剂。

634913-39-6(DMSO)

C15H9ClF6NO5P

463.65 g/mol

C1=CC(=C(C=C1Cl)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)OP(=O)(O)O